Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Sarepta Therapeutics Trading Up 2.5 %

NASDAQ:SRPT traded up $3.08 during trading hours on Monday, hitting $126.79. The company had a trading volume of 741,418 shares, compared to its average volume of 1,221,801. Sarepta Therapeutics, Inc. has a 1 year low of $89.92 and a 1 year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a 50-day moving average of $123.30 and a 200 day moving average of $131.55. The company has a market cap of $12.11 billion, a P/E ratio of 101.43 and a beta of 0.77.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research reports. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Royal Bank of Canada reissued an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a report on Wednesday, November 27th. HC Wainwright decreased their price target on Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a report on Tuesday, December 3rd. Finally, Robert W. Baird dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $178.71.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of SRPT. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $4,771,000. Simplify Asset Management Inc. increased its position in shares of Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock valued at $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Summit Partners Public Asset Management LLC raised its stake in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock valued at $17,250,000 after acquiring an additional 116,800 shares during the period. Finally, Natixis Advisors LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $1,918,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.